BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 27329565)

  • 1. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
    Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN.
    Sugimoto M; Hirama H; Yamaguchi A; Koga H; Hashine K; Ninomiya I; Shinohara N; Maruyama S; Egawa S; Sasaki H; Kakehi Y;
    World J Urol; 2015 Jul; 33(7):981-7. PubMed ID: 25428792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
    Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
    Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year nationwide follow-up study of active surveillance for prostate cancer.
    Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
    Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H; Graefen M
    Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
    Thomsen FB
    Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
    Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.